CellaVision AB (publ) (LON:0MR5)

London flag London · Delayed Price · Currency is GBP · Price in SEK
154.00
-7.00 (-4.35%)
At close: Feb 11, 2026
Market Cap296.75M -21.5%
Revenue (ttm)59.09M +1.5%
Net Income11.95M +0.8%
EPS0.50 +0.8%
Shares Outn/a
PE Ratio24.83
Forward PE20.67
Dividend0.20 (0.12%)
Ex-Dividend DateMay 7, 2025
Volume260
Average Volume1,815
Open161.20
Previous Close161.00
Day's Range154.00 - 158.50
52-Week Range139.80 - 207.50
Beta1.30
RSI49.62
Earnings DateFeb 5, 2026

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 1994
Employees 231
Stock Exchange London Stock Exchange
Ticker Symbol 0MR5
Full Company Profile

Financial Performance

In 2024, CellaVision AB's revenue was 723.22 million, an increase of 6.78% compared to the previous year's 677.29 million. Earnings were 140.72 million, an increase of 7.99%.

Financial numbers in SEK Financial Statements